Oragenics Q3 2026 Results: Net Loss of $2.6M, Loss Narrows
For the nine months ended September 30, 2026, Oragenics reported a net loss of $7.3 million, a slight improvement from the $7.6 million loss in the prior year period. The company's cash position decreased significantly to $2.2 million from $4.4 million at year-end 2025, primarily due to increased research and development spending on its lead product candidate, ONP-002.
- Key figure
- Net loss $2.6M